Photo by nci from unsplash
In an era of controversy in regard to ‘hydroxyurea‐leukaemogenicity’ and when interferon‐alfa2 (IFN) is being revived in the treatment of Philadelphia‐negative myeloproliferative neoplasms (MPNs), we aim in this single‐centre observational… Click to show full abstract
In an era of controversy in regard to ‘hydroxyurea‐leukaemogenicity’ and when interferon‐alfa2 (IFN) is being revived in the treatment of Philadelphia‐negative myeloproliferative neoplasms (MPNs), we aim in this single‐centre observational study to describe the frequencies of second malignancies in a cohort of MPN patients treated with hydroxyurea (HU) or IFN monotherapy or the combination of these agents.
Keywords:
second malignancies;
philadelphia negative;
negative myeloproliferative;
hydroxyurea interferon;
malignancies hydroxyurea;
myeloproliferative neoplasms
Journal Title: European Journal of Haematology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!